Metabolism configures immune response across multi-systems: Lessons from COVID-19

Adv Biol Regul. 2023 Dec:90:100977. doi: 10.1016/j.jbior.2023.100977. Epub 2023 Aug 26.

Abstract

Several studies over the last decade demonstrate the recruitment of immune cells, increased inflammatory cytokines, and chemokine in patients with metabolic diseases, including heart failure, parenchymal inflammation, obesity, tuberculosis, and diabetes mellitus. Metabolic rewiring of immune cells is associated with the severity and prevalence of these diseases. The risk of developing COVID-19/SARS-CoV-2 infection increases in patients with metabolic dysfunction (heart failure, diabetes mellitus, and obesity). Several etiologies, including fatigue, dyspnea, and dizziness, persist even months after COVID-19 infection, commonly known as Post-Acute Sequelae of CoV-2 (PASC) or long COVID. A chronic inflammatory state and metabolic dysfunction are the factors that contribute to long COVID. Here, this study explores the potential link between pathogenic metabolic and immune alterations across different organ systems that could underlie COVID-19 and PASC. These interactions could be utilized for targeted future therapeutic approaches.

Keywords: Immunity; Immunometabolism; Inflammation; Long COVID; Metabolic dysfunction; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Diabetes Mellitus*
  • Heart Failure*
  • Humans
  • Immunity
  • Inflammation
  • Obesity
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2